Scienture Holdings (SCNX) Income from Non-Controlling Interests (2022)
Scienture Holdings' (SCNX) quarterly Income from Non-Controlling Interests came in at -$377843.0 in Q4 2022, down 1367.98% quarter-over-quarter from -$25739.0 in Q3 2022.
Powered by 
Analysis
Scienture Holdings (SCNX) Income from Non-Controlling Interests (2022) Analysis & Trends
Scienture Holdings has disclosed Income from Non-Controlling Interests across 1 years of filings, most recently posting -$377843.0 for Q4 2022.
- In Q4 2022, Income from Non-Controlling Interests changed N/A year-over-year to -$377843.0; the TTM figure through Dec 2022 stood at -$437769.0 (changed N/A YoY), while the FY2025 annual figure was $1.3 million, changed N/A from the prior year.
- Income from Non-Controlling Interests came in at -$377843.0 for Q4 2022 at Scienture Holdings, down from -$25739.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$5689.0 in Q1 2022 to a low of -$377843.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | - |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | - |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | -918,959.97 |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 11.95 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 2.00 Mn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | - |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | - |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | - |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | - |
| 10 | Scienture Holdings | 15.19 Mn | 15.19 Mn | 335,779.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | -377,843.00 |
| Sep 30, 2022 | -25,739.00 |
| Jun 30, 2022 | -28,498.00 |
| Mar 31, 2022 | -5,689.00 |